chamomile tea

PreclinicalSmall molecule

NNational Center for Complementary and Integrative Health (NCCIH)

chamomile tea is one of 37 small molecule programs targeting Abdominal pain. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Abdominal PainActive, not recruiting

Abdominal PainPreclinical

Active, not recruiting

Competition

Competitive Landscape

45 competitors in Abdominal Pain

#DrugCompanyPhaseTrials

Elavil

AstraZeneca

Approved

1 2

Lopid

Niacor

Dilaudid

RRhodes Pharmaceuticals, L.P.

Approved

1 5

MS Contin

HHikma Pharmaceuticals LLC

Approved

1 6

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—7

Naropin

FFresenius Kabi Oncology Ltd.

Approved

—8

Proair HFA

GGlaxo Dba Glaxosmithkline

Marcaine

Chirocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Abdominal pain1 trial

Treatment of Functional Abdominal Pain in Children: Evaluation of Relaxation/Guided Imagery and Chamomile Tea as Therapeutic Modalities

Completed·NNational Center for Complementary and Integrative Health (NCCIH)·N/A·NCT00010933

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for chamomile tea. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — chamomile tea compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for chamomile tea. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Center for Complementary and Integrative Health (NCCIH) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: NNational Center for Complementary and Integrative Health (NCCIH)

chamomile tea

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Abdominal pain1 trial

References

Drug Info

Quick Facts

Related News